Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22116532 | 0.91 | ACACB (0.44) | ACACBHSD17B10MAPK1NPC1RAB9A | |
| SCHEMBL22134655 | 0.85 | ACACB (0.43) | ACACBHSD17B10MAPK1NPC1RAB9A | |
| SCHEMBL22116706 | 0.83 | MAPT (0.44) | ACACBHSD17B10MAPK1NPC1RAB9A | |
| SCHEMBL22116556 | 0.81 | MAPT (0.44) | ACACBMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL22116752 | 0.80 | MAPK1 (0.47) | HSD17B10MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL31620610 | 0.75 | MAPK1 (0.59) | HSD17B10MAPK1NPC1RAB9AP4HTM | |
| SCHEMBL10270980 | 0.75 | MAPK1 (0.59) | HSD17B10MAPK1NPC1RAB9AP4HTM | |
| SCHEMBL22134881 | 0.71 | FFAR1 (0.51) | MAPK1 | |
| SCHEMBL16011728 | 0.71 | MAPK1 (0.57) | HSD17B10MAPK1ALDH1A1MAPTHPGD | |
| SCHEMBL31044611 | 0.71 | MAPK1 (0.57) | HSD17B10MAPK1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351570-B2 | Disubstituted alkyne derivatives | MERCK PATENT GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | disclosed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021249969-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351570-B2 | Disubstituted alkyne derivatives | BRCA1, MYC, PCNA | ACACB 127/4885HSD17B10 1172/4885MAPK1 1307/4885 |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | ACACB 127/4885HSD17B10 1172/4885MAPK1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.